Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a seven-day winning streak.
Biogen announces initiation of dosing in TRANSCEND
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Biogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ...
US close: Uncertainty rattles markets as hectic tariff campaign continues
A step-up in protectionist threats between Canada and the US prompted another negative session on Wall Street on Tuesday, ...
Zacks.com on MSN20h
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.